Standout Papers

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell l... 2017 2026 2020 2023 335
  1. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial (2017)
    Corinne Faivre‐Finn, M. Snee et al. The Lancet Oncology

Immediate Impact

51 standout
Sub-graph 1 of 21

Citing Papers

Non-small-cell lung cancer
2024 Standout
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
2024 Standout
2 intermediate papers

Works of W. Appel being referenced

Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status
2017
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
2017 Standout

Author Peers

Author Last Decade Papers Cites
W. Appel 261 377 104 240 13 595
J L Yeoh 272 430 25 356 10 625
Lee Re 204 146 98 145 23 725
Satoshi Okada 72 109 126 174 22 730
Yoriko De Sanctis 90 170 228 176 24 714
S Sawada 223 88 86 134 18 710
Kyung Cho 148 137 17 192 18 559
Kuhn‐Uk Lee 398 406 67 33 9 696
Mary Ann Hederman 177 131 40 199 12 699
Jenny M. Whitworth 54 190 85 73 22 532
R. Swindell 67 243 45 80 20 598

All Works

Loading papers...

Rankless by CCL
2026